Peptides explained
hCG: how it works
Also known as: Human chorionic gonadotrophin
Page updated · Sources and editorial approach
hCG explained: LH-receptor signalling, reproductive biology and why a licensed fertility medicine has a specific clinical context.
hCG at a glance
What it does biologically
hCG acts through the LH/CG receptor and has roles in reproductive hormone signalling.
What the evidence shows
Specific prescription medicines are used in monitored fertility care. The evidence concerns those products and treatment contexts.
What remains uncertain
A fertility indication does not establish a general bodybuilding, weight-loss or hormone-recovery benefit.
The basics
What is hCG?
Human chorionic gonadotrophin is a glycoprotein hormone. Medicinal preparations include different urinary-derived and recombinant forms; the precise preparation matters.
Choriogonadotropin alfa is a recombinant form used in a specific authorised medicine. A shared hormone name does not make all supplied material pharmaceutically equivalent.
Biological action
How does hCG work?
hCG can activate a receptor shared with luteinising hormone. In ovarian physiology, that signalling participates in final follicular maturation, ovulation and corpus-luteum function.
These actions form part of specialist reproductive care. They should not be turned into a self-directed endocrine regimen or assigned to an unverified preparation.
Questions being investigated
What do studies examine?
Reproductive signalling
Receptor biology explains why hCG appears in fertility medicine.
Clinical endpoints
Studies use defined reproductive outcomes and monitored patient selection.
Formulation differences
Urinary-derived and recombinant preparations require exact identification.
Strength of evidence
How strong is the evidence?
Evidence is separated by level because a cell experiment, an animal model, a human trial and a regulatory decision answer different questions.
| Evidence type | What it tells us |
|---|---|
| Laboratory | LH/CG receptor biology is established. |
| Animal | Preclinical findings do not establish every proposed off-label use. |
| Human | Specific fertility medicines have clinical evidence in defined populations. |
| Regulatory | Authorisation applies to a named prescription medicine and indication, not every hCG-labelled item. |
Important context
Risks, limitations and unanswered questions
- Ovarian hyperstimulation and other reproductive risks require clinical assessment.
- Treatment outcomes depend on the full clinical context.
- A hormone name alone does not establish product identity or an appropriate use.
Reading the original evidence
A fertility outcome needs its original context
The Ovitrelle assessment concerns a defined medicine in fertility care. It does not establish a universal use for every hCG-labelled material. The treatment setting, eligibility, monitoring and measured outcome belong with the finding when it is summarised.
Question to take to the source: Has a finding from a specific fertility indication been extended to a different hormone or performance claim?
Check the original source ↗For personal accounts and research questionnaires, read user feedback and patient-reported outcomes.
Detailed catalogue research
hCG research: chorionic gonadotrophin, fertility and LH signalling
Understand the difference between hCG preparations, their role in monitored fertility care and why the outcome depends on the exact product.
What is hCG and what does the LH/CG receptor do?
Human chorionic gonadotrophin is a glycoprotein hormone that acts through a receptor shared with luteinising hormone. This explains its role in reproductive signalling. hCG, LH and hMG are related to reproductive biology but are not synonymous. Read the full name of the hormone and the named preparation before interpreting a clinical study.
How do recombinant and urinary-derived hCG preparations differ in the evidence?
Studies and prescribing information identify a specific preparation. For example, Ovitrelle contains recombinant choriogonadotropin alfa and has defined uses in fertility care. Evidence on a named medicine is evidence for that preparation and clinical context. It cannot identify a separate hCG-labelled sample or establish how that material would perform.
How should hCG fertility studies and safety findings be read?
Follicular maturation, ovulation and pregnancy are distinct outcomes, and fertility results depend on the full care pathway. Read the population, the monitoring and the comparator before quoting a result. The authorised information describes clinically important risks, including ovarian hyperstimulation in the relevant setting. These studies do not establish unrelated weight-loss or performance claims.
Sources for this research section
Questions answered
hCG FAQs
Is hCG the same as hMG?
No. Their hormone composition and clinical roles differ.
Does a fertility study prove a bodybuilding benefit?
No. A different population and intended outcome require their own evidence.
Check the sources
Sources and further reading
Follow the original study or official information to check the population, methods and full results. Reviews and sponsor updates are labelled below.
- EMA: Ovitrelle assessment ↗Regulatory overview of recombinant hCG in specific fertility care.
- Ovitrelle UK product information ↗Manufacturer's authorised product information, including mechanism and risks.
Educational information, prepared with AI assistance and not independently clinically reviewed. It is not personal medical advice or a treatment recommendation. Read the editorial policy or suggest a correction.